Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

789
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

857
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
857
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-World Outcomes of Dedicated Leaflet Modification for Bioprosthetic Valve-In-Valve TAVR: A 150-Patient Commercial Experience.

JACC. Cardiovascular interventions·2026
Same author

First-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR.

JACC. Case reports·2026
Same author

First-in-Human Transcatheter Aortic Root Tricuspidization of Stenotic Bicuspid Valves: A Strategy to Optimize TAVR.

JACC. Cardiovascular interventions·2026
Same author

Coronary artery calcium on chest CT scans: from incidental finding to mandatory reporting.

Nature reviews. Cardiology·2026
Same author

Current Evidence, Emerging Evidence, and Decision-Making: An Algorithm for Leaflet Modification Procedures.

JACC. Cardiovascular interventions·2026
Same author

First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective Study.

JACC. Cardiovascular interventions·2026
Same journal

[Tennis Elbow Among Players].

Harefuah·2026
Same journal

[Internal Medicine - My Mission].

Harefuah·2026
Same journal

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

Harefuah·2026
Same journal

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

Harefuah·2026
Same journal

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

Harefuah·2026
Same journal

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Harefuah·2026
查看所有相关文章

相关实验视频

Updated: Mar 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

[心脏病学到2030年]

Michael Glikson1, Elad Asher1, Danny Dvir1

  • 1Jesselson Integrated Heart Center and Eisenberg R&D Authority; Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem.

Harefuah
|March 9, 2026
PubMed
概括
此摘要是机器生成的。

最近的心脏病学创新通过人工智能监测,对老年患者的先进干预以及更安全的切除技术来增强患者护理. 新的节拍方法和改进的成像技术进一步推进了心脏治疗.

更多相关视频

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.6K

相关实验视频

Last Updated: Mar 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.6K

科学领域:

  • 心脏病学 心脏病学
  • 心脏重症监护室的重症监护室是心脏重症监护室.
  • 心脏干预 心脏干预
  • 节律失常的管理管理
  • 心脏成像 - - 心脏成像
  • 心脏衰竭治疗方法 治疗方法

背景情况:

  • 心脏病学的最新进展显著影响临床实践.
  • 创新涵盖心脏重症监护,干预,心律失常管理,成像和心力衰竭治疗.

研究的目的:

  • 总结一下最近心脏病学领域的突破.
  • 突出提高患者结果和安全的创新.

主要方法:

  • 审查心脏重症监护的最新发展,包括人工智能监测和机械支持.
  • 老年患者干预性心脏病手术的概述以及对心律失常的新型废除技术.
  • 讨论心脏成像和心力衰竭管理方面的进展.

主要成果:

  • 人工智能算法改善了心脏重症监护中的多模式监测.
  • 脉冲场切除为心律失常治疗提供了更安全的替代方案.
  • 无心脏起器和导电系统节奏代表了心律管理的进步.
  • 3D回声心电图,应变回声心电图和光子计数CT增强了心脏成像.
  • 机械支持在心力衰竭治疗中越来越多地被使用.

结论:

  • 在心脏病学的各个领域取得了重大进展.
  • 这些创新有望提高患者的安全性和治疗效率.